These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

The article highlights three outperforming stocks: Moderna is up 100% year to date, Krystal Biotech is up 38%, and AMD is up 129%. Moderna has multiple clinical and regulatory catalysts ahead, including potential approval for its influenza vaccine mRNA-1010 and future data readouts; Krystal has an expanding market for Vyjuvek and ongoing pipeline catalysts; AMD is framed as a beneficiary of AI demand and gains share versus Intel. Overall, the piece is bullish on all three names, but it is mostly a stock-picking commentary rather than a new market-moving event.

Analysis

The common thread across these names is not just operational momentum, but optionality embedded in underappreciated duration. In biotech, the market is effectively paying for visible cash-flow expansion while assigning little value to pipeline convexity; that creates a favorable setup as long as trial cadence stays clean. In semis, the more important second-order effect is that AI demand is broadening beyond GPUs into CPU-heavy orchestration layers, which should support a longer upgrade cycle for server and desktop silicon than consensus models imply.

Krystal is the cleanest “quality growth” expression here: a single-product base can still re-rate if commercial expansion continues without adoption friction in ex-U.S. markets. The main hidden risk is concentration, not science—any payer, manufacturing, or launch execution issue would matter disproportionately because there is limited portfolio insulation. Moderna, by contrast, is a timing trade: near-term data and approval news can keep the stock working for months, but the real equity value hinges on proving that pipeline assets can compound beyond one or two shots on goal.

AMD looks like the best fundamental/valuation mix of the three because its upside is less dependent on a binary catalyst and more on share gains plus expanding AI TAM. The market may still be underestimating how much CPU content rises in agentic workloads, which is structurally positive for EPYC adoption and pricing. The counterpoint is that after a large year-to-date move, the stock is vulnerable to any digestion period in AI capex; a miss on unit share or a pause in enterprise spending could compress multiple expansion quickly.

The more contrarian read is that the move in these names may be partly a regime bet on duration assets: if rates stay elevated or risk appetite cools, long-duration biotech and AI multiple expansion can stall even if fundamentals remain fine. That suggests the best opportunities are not outright chase longs, but selective exposure with defined downside and catalysts that arrive over the next 1-3 quarters rather than a vague multi-year narrative.

Key Decisions for Investors

• Long AMD vs. short INTC as a relative-value pair for the next 6-12 months; thesis is continued share gains and pricing power, while the short leg is a slower turnaround with higher execution risk. Use a 1:1 notional pair and add on pullbacks if AMD retraces 8-10% without a deterioration in AI demand commentary.
• Buy MRNA on catalyst-driven weakness rather than momentum strength; best entry is after event-driven dips ahead of regulatory readouts. Favor a call spread over outright equity to capture approval upside while limiting downside if one trial disappoints.
• Hold KRYS as a premium-growth compounder, but size it below a typical biotech position because single-asset concentration raises tail risk. Add only if ex-U.S. launch updates confirm no reimbursement or supply bottlenecks; upside remains attractive over 12-24 months if execution stays clean.
• For traders, consider a bullish AMD call spread into the next earnings cycle to express AI upside with defined premium at risk. The setup works best if implied volatility is not already inflated by consensus hype.
• Avoid chasing NVDA and NFLX here; they are secondary beneficiaries in this specific setup and appear less levered to the immediate catalysts than AMD/KRYS. Better risk/reward is in names with visible near-term inflection and less crowded positioning.